Shares of India's Divi's Laboratories Ltd , which makes the main ingredient of Merck & Co's experimental antiviral pill, soared 10% on Monday, after the pharmaceutical giant reported positive clinical trial results for the drug.
, which are jointly conducting a clinical trial in India with molnupiravir, also gained between 1.1% and 2.3%.
In July, privately held Hetero Labs said it was also seeking a domestic emergency use nod for the experimental treatment, after interim data from its late-stage trial showed molnupiravir helped reduce hospitalisations in mild cases of COVID-19.More from ReutersSubscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
India Aims to Produce mRNA Covid-19 Vaccine This YearA government-backed push to develop a new shot would expand the nation’s pharmaceutical industry and improve global production and distribution options.
Les mer »
Several killed in northern India as car runs over protesting farmersCar linked to federal minister runs over farmers, killing four of them while four more people are killed in ensuing violence in Uttar Pradesh state's Lakhimpur Kheri district, farmers and officials say.
Les mer »
Merck’s Covid-19 Drug Is a Boon for Wall Street and Main StreetMerck and partner Ridgeback Biotherapeutics released strong data for their new Covid-19 pill. WSJheard explains how this could be a boon on Main Street and Wall Street. WSJWhatsNow
Les mer »
Supreme Court Justice Brett Kavanaugh Tests Positive for COVIDSupreme Court justice Brett Kavanaugh tests positive for COVID-19 despite being fully vaccinated since January.
Les mer »
Merck COVID-19 treatment pill could be available by end of year, Dr. Adalja predictsJohns Hopkins School of Public Health Dr. Amesh Adalja expresses his optimism for Merck's new coronavirus treatment on 'Fox News Live.'
Les mer »
Why a pill you take at home could change the direction of the pandemicMerck and Ridgeback Therapeutics Inc.'s promising oral antiviral could shift the direction of the pandemic by making it easier for people with COVID-19 to...
Les mer »